The 2020 Annual Conference of the National Inflammatory Bowel Disease Group and the 2020 Yunnan Congress of Digestive Disease were held in Kunming, Yunnan Province, from July 31 to August 2.
The 2020 Annual Conference of the National Inflammatory Bowel Disease Group and the 2020 Yunnan Congress of Digestive Disease were held in Kunming, Yunnan Province, from July 31 to August 2. The conference was sponsored by the Inflammatory Bowel Disease Group of Chinese Society of Gastroenterology, China Health Promotion Foundation, the Gastroenterology and Gastrointestinal Endoscopy Branch of Chinese Medical Association Yunnan Branch, and the Zhongguancun Zhuoyi Institute of Science and Technology Innovation for Chronic Disease Prevention and Control, and hosted by the First Affiliated Hospital of Kunming Medical University, and co-organized by the First Affiliated Hospital of Sun Yat-sen University, Xijing Hospital of Air Force Medical University, Peking Union Medical College Hospital, and West China Hospital of Sichuan University. SINOWAY Pharmaceutical is one of the sponsors of the conference, providing corresponding support for the conference.
This conference aimed to promote academic exchange and development of gastroenterology in Yunnan Province, so as to improve the academic level of clinicians and the ability to handle difficult clinical cases continuously, to enhance the academic level and management of IBD (Inflammatory Bowel Disease) among gastroenterologists, and to guide innovative research that closely follows the frontiers.
The conference, combining online and offline participation modes, invited renowned experts in related fields to give presentations on hot topics and carry out exciting interpretations of difficult issues. It had built a bridge for exchanging cutting-edge scientific issues among participating parties, enabling them to discuss nursing-related issues. During the two and half days of the conference, different forums had seen different cutting-edge hot knowledge on issues like inflammatory bowel disease and chronic liver disease, new advances in IBD enteral nutrition, HP-negative gastric cancer, prospects of combining biologic drugs with different mechanisms of action, epidemiological trends and disease characteristics of inflammatory bowel disease in China, and diagnosis and treatment of IBD complicated with liver disease.
In the conference, the Company invited relevant experts of Renji Hospital affiliated to Medical College of Shanghai Jiaotong University to interpret the consensus opinion on H. pylori eradication and gastric cancer control and prevention in China. The Consensus Opinion points out that H. pylori infection is the main cause of gastric cancer in China, public awareness of gastric cancer prevention should be increased, the harm of H. pylori infection should be fully understood, and the standard bismuth quadruple regimen is recommended for H. pylori eradication, which can help the prevention and treatment of gastric cancer.
An exhibition area was set up for display during the conference, attracting a number of well-known pharmaceutical companies to attend. As a local enterprise in Kunming, SINOWAY Pharmaceutical demonstrated our original product Kangfuxin Liquid to all parties attending the conference.